Study details
Enrolling now
AlloSCT for Blood Disorders
Mitchell Cairo
NCT IDNCT04099966ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
20
Study length
about 6.8 years
Ages
0.00273790700698851–30
Locations
1 site in NY
About this study
This trial is testing a new way to prepare stem cells before an allogeneic stem cell transplant (AlloSCT) for people with blood disorders. The treatment involves removing certain immune cells from the stem cells using alpha/beta depletion. This may help improve outcomes for patients undergoing AlloSCT.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take alpha beta depletion
PhasePhase 2
Primary goalincidence of adverse events related to administration of α/β CD3+/CD19+ cell depleted stem cells
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: incidence of adverse events related to administration of α/β CD3+/CD19+ cell depleted stem cells
Body systems
Oncology